Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Bristol-Myers Squibb Company is placed third among them.

Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader in oncology, immunology, cardiovascular disease, and fibrosis, is undergoing major strategic changes as it adapts to shifting market conditions.

On September 17, 2025, the company announced plans to divest its 60% stake in a pharmaceutical joint venture in China. The move reflects a broader realignment as BMY joins other drugmakers in reducing exposure to China amid economic headwinds and supply chain challenges.

The divestiture comes alongside a $2.5 billion restructuring plan launched in 2023 aimed at cutting costs and driving efficiency. The program, expected to yield $2 billion in annual savings by 2027, involves reshaping R&D, commercial, and manufacturing operations. Workforce reductions are a key component, with 282 layoffs in New Jersey scheduled between December 2025 and March 2026. In total, the firm expects to save about $3.5 billion through multiple rounds of staff reductions and operational improvements.

Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment

Financially, Bristol-Myers Squibb Company (NYSE:BMY) will report Q3 2025 results on October 30, with analysts projecting earnings of $1.65 per share. BMY also reaffirmed shareholder returns, declaring a quarterly dividend of $0.62 per share on September 17.

While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.